The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. METHODS: We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. RESULTS: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2(R172) mutations (in 1%). Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene-gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. CONCLUSIONS: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 391 out of the 622 curated COSMIC cancer-related and AML-related genes located inside the altered TADs in at least one sample, and more than 100 are recurrent across multiple samples (Extended Data Fig. 3b)4,24,25.”
From Subtype-specific 3D genome alteration in acute myeloid leukaemia (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Papaemmanuil et al. 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Leukemia is frequently driven by mutations in epigenetic modifiers or signaling master regulators58 that lead to gross alterations of the epigenetic landscape59 and an epigenetic environment widely permissive of activation.”
From Design principles of cell-state-specific enhancers in hematopoiesis (2025) · cites this paper as [58]
In the citing paper
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationGrimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,031
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Cited by
Sorted by citations
Items 301–400 of 1,007
Acfs: accurate circRNA identification and quantification from RNA-Seq data
You, X. A., & Conrad, T. (2016) · Scientific Reports · doi:10.1038/srep38820 · Cited by 94
TET2 in Normal and Malignant HematopoiesisPreprint
Bowman, R. L., & Levine, R. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026518 · Cited by 102
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91
Okada, T., Lee, A. Y., Qin, L., Agaram, N. P., Mimae, T., Shen, Y., O’Connor, R., López-Lago, M. A., Craig, A. J., Miller, M. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1481 · Cited by 90
Chaudhury, S., O’Connor, C., Cañete, A., Bittencourt‐Silvestre, J., Sarrou, E., Prendergast, Á. M., Choi, J., Johnston, P., Wells, C. A., Gibson, B. E. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07584-1 · Cited by 92
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 100
Eisfeld, A., Kohlschmidt, J., Mims, A. S., Nicolet, D., Walker, C. J., Blachly, J. S., Carroll, A. J., Papaioannou, D., Kolitz, J. E., Powell, B., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0872-3 · Cited by 90
Tóthová, Z., Valton, A.-L., Gorelov, R. A., Vallurupalli, M., Krill-Burger, J. M., Holmes, A. L., Landers, C. C., Haydu, J. E., Małolepsza, E., Hartigan, C. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142149 · Cited by 90
Guiding the global evolution of cytogenetic testing for hematologic malignancies
Akkari, Y. M. N., Baughn, L. B., Dubuc, A. M., Smith, A. C., Mallo, M., Cin, P. D., Díez‐Campelo, M., Gallego, M. S., Granada, I., Haase, D. T., et al. (2022) · Blood · doi:10.1182/blood.2021014309 · Cited by 92
Trino, S., Lamorte, D., Caivano, A., Laurenzana, I., Tagliaferri, D., Falco, G., Vecchio, L. D., Musto, P., & Luca, L. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020460 · Cited by 90
Evolution and progression of Barrett’s oesophagus to oesophageal cancer
Killcoyne, S., & Fitzgerald, R. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00400-x · Cited by 90
Garcia‐Manero, G., Goldberg, A. D., Winer, E. S., Altman, J. K., Fathi, A. T., Odenike, O. M., Roboz, G. J., Sweet, K. L., Miller, C., Wennborg, A., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00403-3 · Cited by 91
Molecular taxonomy of myelodysplastic syndromes and its clinical implications
Bernard, E., Hasserjian, R. P., Greenberg, P. L., Ossa, J. A., Creignou, M., Tuechler, H., Gutiérrez‐Abril, J., Domenico, D., Medina-Martinez, J. S., Levine, M. F., et al. (2024) · Blood · doi:10.1182/blood.2023023727 · Cited by 89
Self-citationCraddock, C. F., Houlton, A. E., Quek, L. S., Ferguson, P., Gbandi, E., Roberts, C., Metzner, M., Garcia-Martin, N., Kennedy, A., Hamblin, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1423 · Cited by 88
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
Patel, S. S., Kuo, F. C., Gibson, C. J., Steensma, D. P., Soiffer, R. J., Alyea, E. P., Chen, Y.-B. A., Fathi, A. T., Graubert, T. A., Brunner, A. M., et al. (2018) · Blood · doi:10.1182/blood-2018-01-828467 · Cited by 88
Single cell analysis of clonal architecture in acute myeloid leukaemia
Potter, N. E., Miraki‐Moud, F., Ermini, L., Titley, I., Vijayaraghavan, G., Papaemmanuil, E., Campbell, P. J., Gribben, J. G., Taussig, D. C., & Greaves, M. F. (2018) · Leukemia · doi:10.1038/s41375-018-0319-2 · Cited by 92
Self-citationThe splicing factor RBM25 controls MYC activity in acute myeloid leukemia
Ge, Y. C., Schuster, M. B., Pundhir, S., Rapin, N., Bagger, F. O., Sidiropoulos, N., Hashem, N. B., & Porse, B. T. (2019) · Nature Communications · doi:10.1038/s41467-018-08076-y · Cited by 91
Mrózek, K., Eisfeld, A., Kohlschmidt, J., Carroll, A. J., Walker, C. J., Nicolet, D., Blachly, J. S., Bill, M., Papaioannou, D., Wang, E. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0390-3 · Cited by 88
How I investigate acute myeloid leukemia
Narayanan, D., & Weinberg, O. K. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13135 · Cited by 88
Gardin, C., Pautas, C., Fournier, É., Itzykson, R., Lemasle, É., Bourhis, J.-H., Adès, L., Marolleau, J., Malfuson, J., Gastaud, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001349 · Cited by 88
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells
Raffel, S., Klimmeck, D., Falcone, M., Demir, A., Pouya, A., Zeisberger, P., Lutz, C., Tinelli, M., Bischel, O. E., Bullinger, L., et al. (2020) · Blood · doi:10.1182/blood.2019003654 · Cited by 91
Self-citationLoizou, E., Banito, A., Livshits, G., Ho, Y.-J., Koche, R. P., Sánchez-Rivera, F. J., Mayle, A., Chen, C.-C., Kinalis, S., Bagger, F. O., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1391 · Cited by 88
Dumas, P., Naudin, C., Martin‐Lannerée, S., Izac, B., Casetti, L., Mansier, O., Rousseau, B., Artus, A., Dufossée, M., Giese, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205385 · Cited by 90
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
Bohl, S., Bullinger, L., & Rücker, F. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081983 · Cited by 89
Self-citationGilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Zhao, J.-J., Song, Y., & Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0170-2 · Cited by 88
Demaree, B., Delley, C. L., Vasudevan, H. N., Peretz, C. A. C., Ruff, D., Smith, C. C., & Abate, A. R. (2021) · Nature Communications · doi:10.1038/s41467-021-21810-3 · Cited by 91
Arellano, M. L., Thirman, M. J., DiPersio, J. F., Heiblig, M., Stein, E. M., Schuh, A. C., Žučenka, A., de Botton, S., Grove, C. S., Mannis, G. N., et al. (2025) · Blood · doi:10.1182/blood.2025028357 · Cited by 86
Self-citationManaging Clonal Hematopoiesis in Patients With Solid Tumors
Bolton, K. L., Gillis, N., Coombs, C. C., Takahashi, K., Zehir, A., Bejar, R. L., Garcia‐Manero, G., Futreal, P. A., Jensen, B. C., Diaz, L. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00331 · Cited by 87
Self-citationEpigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Brown, F. C., Still, E., Koche, R. P., Yim, C. Y., Takao, S., Cifani, P., Reed, C., Gunasekera, S., Ficarro, S. B., Romanienko, P. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1271 · Cited by 85
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 88
Cole, C. B., Russler-Germain, D. A., Ketkar, S., Verdoni, A. M., Smith, A. M., Bangert, C. V., Helton, N. M., Guo, M., Klco, J. M., O’Laughlin, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93041 · Cited by 84
Long, J., Jia, M.-Y., Fang, W.-Y., Chen, X.-J., Mu, L.-L., Wang, Z.-Y., Shen, Y., Xiang, R.-F., Wang, L.-N., Wang, L., et al. (2020) · Blood · doi:10.1182/blood.2019003538 · Cited by 84
Zhang, F., Lu, Y., Wang, M., Zhu, J., Li, J., Zhang, P., Yuan, Y., & Zhu, F. (2020) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2020.101513 · Cited by 84
Stetson, L. C., Balasubramanian, D., Ribeiro, S. P., Stefan, T., Gupta, K., Xu, X., Fourati, S., Roe, A. J., Jackson, Z., Schauner, R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01338-7 · Cited by 85
Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Wulf, G. G., Salih, H. R., Lübbert, M., Kühn, M. W. M., Schroeder, T. A., Salwender, H. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007223 · Cited by 86
Self-citationThe International Consensus Classification of acute myeloid leukemia
Weinberg, O. K., Porwit‐MacDonald, A., Orazi, A., Hasserjian, R. P., Foucar, K. K., Duncavage, E. J., & Arber, D. A. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03430-4 · Cited by 84
Bruedigam, C., Porter, A. H., Song, A., de Wei, G. V. I., Stoll, T. M., Straube, J., Cooper, L. T., Cheng, G., Kahl, V. F. S., Sobinoff, A. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00653-5 · Cited by 86
Self-citationTargeting apoptosis in acute myeloid leukaemia
Cassier, P. A., Castets, M., Belhabri, A., & Vey, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.281 · Cited by 86
Ochi, Y., Kon, A., Sakata, T., Nakagawa, M. M., Nakazawa, N., Kakuta, M., Kataoka, K., Koseki, H., Nakayama, M., Morishita, D., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0982 · Cited by 86
Awada, H. K., Durmaz, A., Gurnari, C., Kishtagari, A., Meggendorfer, M., Kerr, C. M., Kuzmanovic, T., Durrani, J., Shreve, J. T., Nagata, Y., et al. (2021) · Blood · doi:10.1182/blood.2020010603 · Cited by 83
Xuan, L., Wang, Y., Yang, K., Shao, R., Huang, F., Fan, Z., Chi, P., Xu, Y., Xu, N., Deng, L., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00117-5 · Cited by 83
What have we learned about TP53-mutated acute myeloid leukemia?
Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 88
Leonard, J. P., Martin, P., & Roboz, G. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6745 · Cited by 83
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia
Gregory, M. A., Nemkov, T. G., Reisz, J. A., Zaberezhnyy, V., Hansen, K. C., D’Alessandro, A., & DeGregori, J. V. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.007 · Cited by 82
ETV6-related thrombocytopenia and leukemia predisposition
Paola, J. D., & Porter, C. C. (2019) · Blood · doi:10.1182/blood.2019852418 · Cited by 84
Classification of acute myeloid leukemia
Hwang, S. M. (2020) · Blood Research · doi:10.5045/br.2020.s001 · Cited by 91
Rücker, F. G., Du, L., Luck, T. J., Benner, A., Krzykalla, J., Gathmann, I., Voso, M. T., Amadori, S., Prior, T. W., Brandwein, J. M., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01323-0 · Cited by 82
Self-citationTiming somatic events in the evolution of cancer
Jolly, C., & Loo, P. V. (2018) · Genome biology · doi:10.1186/s13059-018-1476-3 · Cited by 86
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
Zhang, H., Wilmot, B., Bottomly, D., Dao, K.-H. T., Stevens, E. A., Eide, C. A., Khanna, V., Rofelty, A., Savage, S. L., Schultz, A. R., et al. (2019) · Blood · doi:10.1182/blood.2019000611 · Cited by 82
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 85
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
Staudt, D. E., Murray, H. C., McLachlan, T., Alvaro, F., Enjeti, A. K., Verrills, N. M., & Dun, M. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103198 · Cited by 82
The power and potential of integrated diagnostics in acute myeloid leukaemia
Haferlach, T., & Schmidts, I. (2019) · British Journal of Haematology · doi:10.1111/bjh.16360 · Cited by 81
Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia
Ottema, S., Mulet‐Lazaro, R., Beverloo, H. B., Erpelinck-Verschueren, C. A. J., van Herk, S., van der Helm, R. M., Havermans, M., Grob, T., Valk, P. J. M., Bindels, E. M., et al. (2020) · Blood · doi:10.1182/blood.2019003701 · Cited by 81
Potential targeting of FLT3 acute myeloid leukemia
Ambinder, A. J., & Levis, M. J. (2020) · Haematologica · doi:10.3324/haematol.2019.240754 · Cited by 80
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
Samra, B., Konopleva, M. Y., Isidori, A., Daver, N. G., & Dinardo, C. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.562558 · Cited by 86
Scholl, S., Fleischmann, M., Schnetzke, U., & Heidel, F. H. (2020) · Cells · doi:10.3390/cells9112493 · Cited by 80
Coppola, G., & Candoni, A. (2024) · Hematology Reports · doi:10.3390/hematolrep16020024 · Cited by 80
Current Management of Childhood Acute Myeloid Leukemia
Rubnitz, J. E. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0200-6 · Cited by 79
Hou, H., & Tien, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00674-7 · Cited by 86
Xie, G., Ivica, N. A., Jia, B., Li, Y., Dong, H., Liang, Y., Brown, D. R., Romee, R., & Chen, J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00625-5 · Cited by 79
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Aitken, M. J. L., Ravandi, F., Patel, K. P., & Short, N. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01148-5 · Cited by 79
Othman, J., Tiong, I. S., O’Nions, J., Dennis, M., Mokretar, K., Ivey, A., Austin, M. J., Latif, A., Amer, M., Chan, W. Y., et al. (2023) · Blood · doi:10.1182/blood.2023021579 · Cited by 79
Self-citationMutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Quek, L. S., Ferguson, P., Metzner, M., Ahmed, I., Kennedy, A., Garnett, C., Jeffries, S., Walter, C. U., Piechocki, K., Timbs, A., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000760 · Cited by 81
RUNX1 Mutations in Inherited and Sporadic Leukemia
Bellissimo, D. C., & Speck, N. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00111 · Cited by 81
Chan, A., & Chen, C.-W. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00081 · Cited by 83
Targeting Metabolic Reprogramming in Acute Myeloid Leukemia
Castro, I., Sampaio‐Marques, B., & Ludovico, P. (2019) · Cells · doi:10.3390/cells8090967 · Cited by 79
TET methylcytosine oxidases: new insights from a decade of research
Lio, C. J., Yue, X., López-Moyado, I. F., Tahiliani, M., Aravind, L., & Rao, A. (2020) · Journal of Biosciences · doi:10.1007/s12038-019-9973-4 · Cited by 80
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
Boddu, P. C., Kantarjian, H. M., Borthakur, G. M., Kadia, T. M., Daver, N. G., Pierce, S. A., Andreeff, M., Ravandi, F., Cortes, J. E., & Kornblau, S. M. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009019 · Cited by 78
Lee, D. J., & Zeidner, J. F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1678583 · Cited by 78
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia
Bjelosevic, S., Gruber, E., Newbold, A., Shembrey, C., Devlin, J. R., Hogg, S. J., Kats, L. M., Todorovski, I., Fan, Z., Abrehart, T. C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0738 · Cited by 79
Treatment for Relapsed/Refractory Acute Myeloid Leukemia
Thol, F. R., & Heuser, M. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000572 · Cited by 77
Self-citationCheng, W., Li, J., Zhu, Y., Lin, X., Wen, L., Zhang, F., Zhang, Y., Zhao, M., Fang, H., Wang, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211429119 · Cited by 78
Bamopoulos, S. A., Batcha, A. M. N., Jurinović, V., Rothenberg‐Thurley, M., Janke, H., Ksienzyk, B., Philippou‐Massier, J., Graf, A., Krebs, S., Blum, H., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0839-4 · Cited by 77
How I diagnose and treat NPM1 -mutated AML
Falini, B., Brunetti, L., & Martelli, M. P. (2020) · Blood · doi:10.1182/blood.2020008211 · Cited by 78
BRD4-mediated repression of p53 is a target for combination therapy in AML
Latif, A., Newcombe, A., Li, S., Gilroy, K. L., Robertson, N., Lei, X., Helen, S., Cole, J. J., Terradas-Terradas, M., Rishi, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20378-8 · Cited by 76
Wang, T., Pine, A. R., Kotini, A. G., Yuan, H., Zamparo, L., Starczynowski, D. T., Leslie, C. S., & Papapetrou, E. P. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.011 · Cited by 77
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Wysota, M., Konopleva, M. Y., & Mitchell, S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01503-y · Cited by 76
Ferrone, C. K., Blydt-Hansen, M., & Rauh, M. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020626 · Cited by 80
Sellar, R. S., Sperling, A. S., Slabicki, M. M., Gasser, J. A., McConkey, M. E., Donovan, K. A., Mageed, N., Adams, D. N., Zou, C., Miller, P. G., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153514 · Cited by 76
Next-Generation sequencing transforming clinical practice and precision medicine
Yadav, D., Patil‐Takbhate, B., Khandagale, A. S., Bhawalkar, J., Tripathy, S. P., & Khopkar-Kale, P. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117568 · Cited by 79
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Blanco, T. M., Dimitriou, M., Woll, P. S., Karimi, M., Elvarsdóttir, E. M., Conte, S., Tobiasson, M., Jansson, M., Douagi, I., Moarii, M., et al. (2017) · Blood · doi:10.1182/blood-2017-03-776070 · Cited by 80
Self-citationTargeting splicing abnormalities in cancer
Agrawal, A. A., Yu, L., Smith, P. G., & Buonamici, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.010 · Cited by 79
Huang, R., Liao, X., & Li, Q. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s147717 · Cited by 74
Schroeder, T. A., Rautenberg, C., Krüger, W., Platzbecker, U., Bug, G., Lohmeyer, J. K., Klein, S., Hopfer, O., Nachtkamp, K., Kondakci, M., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3185-5 · Cited by 74
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia
Alfayez, M., Issa, G. C., Patel, K. P., Wang, F., Wang, X., Short, N. J., Cortes, J. E., Kadia, T. M., Ravandi, F., Pierce, S. A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0920-z · Cited by 74
Bazarbachi, A. A., Schmid, C., Labopin, M., Beelen, D. W., Blau, I. W., Potter, V. T., Niittyvuopio, R., Socié, G., Blaise, D., Sanz, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3134 · Cited by 74
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
Jahn, N., Terzer, T., Sträng, E., Dolnik, A., Cocciardi, S., Panina, E., Corbacioglu, A., Herzig, J., Weber, D., Schrade, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002673 · Cited by 74
Self-citationClinical Implications of Inflammation in Acute Myeloid Leukemia
Récher, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.623952 · Cited by 80
Mitochondrial metabolism as a target for acute myeloid leukemia treatment
Panina, S., Pei, J., & Kirienko, N. V. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00253-w · Cited by 74
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Stubbins, R. J., & Karsan, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00584-3 · Cited by 75
Wang, B., Reville, P. K., Yassouf, M. Y., Jelloul, F. Z., Ly, C. P., Desai, P. N., Wang, Z., Borges, P., Veletić, I., Dasdemir, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45916-6 · Cited by 76
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct forFLT3-ITD acute myeloid leukemia
Lam, S. S. Y., Ho, E. S. K., He, A. B.-L., Wong, W.-W., Cher, C. Y., Ng, N. K. L., Man, C., Gill, H., Cheung, A. M. S., Ip, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3735 · Cited by 74
Leisch, M., Jansko, B., Zaborsky, N., Greil, R., & Pleyer, L. (2019) · Cancers · doi:10.3390/cancers11020252 · Cited by 76
Richard‐Carpentier, G., & Dinardo, C. D. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719882822 · Cited by 74
Targeted Therapies for Pediatric AML: Gaps and Perspective
Lonetti, A., Pession, A., & Masetti, R. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00463 · Cited by 73
Murdock, H. M., Kim, H. T., Denlinger, N., Vachhani, P. J., Hambley, B. C., Manning, B. S., Gier, S. H., Cho, C., Tsai, H. K., McCurdy, S. R., et al. (2022) · Blood · doi:10.1182/blood.2021014520 · Cited by 73
Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis
Magina, K. N., Pregartner, G., Zebisch, A., Wölfler, A., Neumeister, P., Greinix, H. T., Berghold, A., & Sill, H. (2017) · Blood · doi:10.1182/blood-2017-04-777722 · Cited by 73
Classification and risk assessment in AML: integrating cytogenetics and molecular profiling
Moarii, M., & Papaemmanuil, E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.37 · Cited by 76
Self-citationChen, Y., Tyagi, D., Lyu, M., Carrier, A. J., Nganou, C., Youden, B., Wang, W., Cui, S., Servos, M. R., Oakes, K. D., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05432 · Cited by 72
Metadata
- Authors
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., Teague, J. W., Butler, A. P., Greaves, M. F., Ganser, A., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J.
- Affiliations
- European Bioinformatics Institute (GB)
- Wellcome Sanger Institute (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2209-2221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4979995
- OpenAlex
- W2419140434
- Cited by
- 4,350
- References
- 40
- Citations by year
- 2026: 345 · 2025: 403 · 2024: 468 · 2023: 460 · 2022: 551 · 2021: 583 · 2020: 481 · 2019: 415 · 2018: 286 · 2017: 282 · 2016: 63
- FWCI
- 331.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (103858/Z/14/Z, 105104, 077012/Z/05/Z, 077012, 103858, 105104/Z/14/Z, WT088340MA)
- Francis Crick Institute (10202)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- acute myeloid leukemia, driver mutations, genomic subgroups, prognostic stratification, TP53 mutation, aneuploidy, NPM1 mutation, IDH2 mutation, gene-gene interaction, co-mutation patterns, overall survival, intensive treatment
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Adult, DNA (Cytosine-5-)-Methyltransferases, DNA Mutational Analysis, Epistasis, Genetic, Genotype, Humans, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Prospective Studies, RNA Splicing, Leukemia, Myeloid, Acute, Proportional Hazards Models, Survival Analysis, Intracellular Signaling Peptides and Proteins, Gene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
